Baker Bros. Advisors LP Nektar Therapeutics Transaction History

Baker Bros. Advisors LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $12.7 Million - $28.8 Million	-275,396 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $5.94 Million - $11.2 Million	103,462 Added 60.18%	275,396 $29.3 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $3.96 Million - $10.4 Million	171,934	171,934 $10.3 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.